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Fatigue Profiles in Patients with 
Multiple Sclerosis are Based on 
Severity of Fatigue and not on 
Dimensions of Fatigue
Heleen Beckerman  1,2,3*, Isaline CJM eijssen1,2,3, Jetty van Meeteren4, 
Marion C Verhulsdonck5 & Vincent de Groot1,2,3
Fatigue related to Multiple Sclerosis (MS) is considered a multidimensional symptom, manifesting in 
several dimensions such as physical, cognitive, and psychosocial fatigue. This study investigated in 264 
patients with severe primary MS-related fatigue (median MS duration 6.8 years, mean age 48.1 years, 
75% women) whether subgroups can be distinguished based on these dimensions. Subsequently, we 
tested whether MS-related fatigue consists of a single common unidimensional factor. Subscale scores 
on four self-reported fatigue questionnaires, including the Checklist of Individual Strength, the Modified 
Fatigue Impact Scale, the Fatigue Severity Scale and the SF36 vitality, were used in a cluster analysis 
to identify patients with similar fatigue characteristics. Next, all 54 items were included in exploratory 
factor analysis to test unidimensionality. Study results show that in patients with a treatment indication 
for primary MS-related fatigue, fatigue profiles are based on severity and not on the various dimensions 
of fatigue. The three profiles found, suggested one underlying fatigue dimension, but this could not 
be confirmed. Factor analysis of all 54 items resulted in 8 factors, confirming the multidimensional 
construct of the included fatigue questionnaires.
Multiple sclerosis-related fatigue is a disabling symptom that affects most patients during the neuroprogressive 
course of the disease1–4. MS-related fatigue is a puzzling interplay between multiple genotypic and phenotypic 
factors5,6. Fatigue can be caused either directly by the MS disease process in the central nervous system (i.e. pri-
mary fatigue), initiated by inflammatory processes associated with immune activation, demyelination, axonal loss 
or neuroendocrine disturbance, or indirectly by other problems (i.e. secondary fatigue) such as insomnia, sleep 
disturbance due to urge incontinence or spasticity, acute infections, thyroid disorders, physical inactivity and 
deconditioning, or depression. In all cases, a correct differential diagnosis is required for proper clinical decision 
making.
There are many definitions of fatigue (see Supplementary Information 1 for references regarding Fatigue 
Definitions) and over 250 ways to measure fatigue7. Examples of frequently used definitions of MS-related fatigue 
include: the reduction in performance following either prolonged or unusual exertion, together with feelings of 
sensory, motor, cognitive or subjective fatigue8; a subjective lack of physical and/or mental energy that is per-
ceived by the individual or caregiver to interfere with usual and desired activities9; the perception of decreased 
mental or physical energy that may restrict routines of daily activities10; the failure to initiate and/or sustain atten-
tional tasks (mental or cognitive fatigue) and physical activities (physical fatigue)5.
Dittner et al.11 recognized the wide range of fatigue definitions as a so-called Catch-22 situation: “Before a 
concept can be measured, it must be defined, and before a definition can be agreed, there must exist an instrument 
for assessing phenomenology. There is unfortunately no “gold standard” for fatigue, nor is there ever likely to 
be”. This Catch-22 situation has caused many researchers to struggle with the assessment, understanding, etiol-
ogy and classification of fatigue within different patient groups. To produce a workable solution, proposals were 
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made to distinguish non-pathological or normal physiological fatigue from pathological fatigue, general from 
disease-specific fatigue, brief or acute periods of fatigue from chronic fatigue, and central from peripheral fatigue, 
(i.e., muscle fatigability due to disorders of muscle and neuromuscular junctions)5,12–15. Furthermore, recent evi-
dence suggests that perceived fatigue and energy should be investigated separately as they seem to be two inde-
pendent constructs16. The many elements of fatigue in neurological diseases were included in a proposed unified 
taxonomy for fatigue, including an assessment approach to addressing distinct aspects of fatigue and fatigability 
in clinical and research settings6.
In patients with MS, fatigue is considered a multidimensional symptom, manifesting itself in distinct dimen-
sions such as physical, cognitive, and psychosocial fatigue. Assessing perceived fatigue in patients with MS is 
complex due to its multidimensional and non-objectively verifiable character. The most commonly used methods 
in clinical practice and research are self-reported questionnaires, and many valid, reliable, and responsive unidi-
mensional and multidimensional fatigue questionnaires are currently available. See Supplementary Information 2 
for references regarding systematic reviews of fatigue instruments.
Fatigue questionnaires vary greatly regarding the factors examined and may include questions on severity or 
intensity, duration, momentary perceptions, chronic character, dimensions of fatigue (e.g. mental vs. physical), 
affective meaning and distress (e.g. motivation), impact of fatigue on daily functioning, behavioural interference 
with activities and ratings of related constructs (e.g. tiredness or sleepiness) (Supplementary Information 2). As 
in other diagnostic areas, there is currently no consensus regarding the ideal core set of fatigue questions needed 
to study MS-related fatigue17–20.
In MS rehabilitation and research, multidimensional fatigue scales are most often used. However, scores 
on subscales of multidimensional fatigue questionnaires are often presented separately, without showing their 
mutual relationship in individual patients. On the other hand, the presentation of total scores on multidimen-
sional scales results in the loss of information on the underlying individual dimensions21.
Developing fatigue profiles might help reduce the number of measurement instruments, and might facilitate 
decision making on which instruments should be used and which qualify as redundant. More importantly, a 
patient’s fatigue profile might facilitate clinical decision making with regard to the content and specificity of 
treatment. Indeed, a clear distinction between different fatigue profiles that show the involvement of a certain 
domain (e.g. cognitive fatigue or physical activity-induced fatigue) would create opportunities for patient-tailored 
fatigue treatments. Differentiation between fatigue profiles might also help to detect specific treatment effects and 
to explain the underlying mechanisms of treatment interventions such as aerobic training, energy conservation 
management and cognitive behavioural therapy22.
The objectives of this study were twofold: (1) to investigate whether in patients with a treatment indication for 
severe primary MS-related fatigue, fatigue profiles are based on the various dimensions of fatigue, and (2) to test 
whether there is a single common unidimensional factor model of perceived fatigue in patients with MS.
Methods
Design. Baseline data on 264 participants from the TREFAMS-ACE trials were analysed. TREFAMS is an 
acronym for the TReating FAtigue in MS programme, and ACE refers to the rehabilitation treatment meth-
ods under study, specifically Aerobic training, Cognitive Behavioural Therapy, and Energy Conservation 
Management22. The TREFAMS-ACE research programme included three multicentre randomised clinical trials 
(RCTs) and one explanatory study on the biological mechanisms that underlie MS-related fatigue in general and 
the treatment effects in particular. The patient enrolment process consisted of a clinical visit in which a rehabili-
tation physician checked the inclusion and exclusion criteria. After inclusion, self-reported questionnaires were 
offered to participants via internet or on paper and were completed at home. Filling in the study questionnaires 
took about 90 minutes. Patients were advised to filling in the questionnaires with some breaks within 1–2 days. 
The completion had to be ready before randomization to the trial interventions. The list of measurement instru-
ments used in the TREFAMS-ACE studies can be found in our Trials paper of 201322.
Patients. Enrolment criteria were designed to include severely primarily fatigued MS patients who all had 
a treatment indication because of their severe fatigue symptoms, but exclude secondary fatigue. Patients had 
to fulfil the following inclusion criteria: (a) definitive diagnosis of MS, (b) severely fatigued (i.e. a score on the 
Checklist of Individual Strengths (CIS20r) fatigue subscale ≥ 35), (c) ambulatory patients, (d) no evident signs of 
an MS exacerbation or corticosteroid treatment in the past 3 months, (e) no current infections, (f) no anaemia, 
and (g) normal thyroid function. The exclusion criteria were: (a) depression, (b) primary sleep disorders, (c) 
severe co-morbidity (i.e. Cumulative Illness Rating Scale item scores ≥ 3), (d) current pregnancy or having given 
birth in the past 3 months, (e) pharmacological treatment for fatigue that was started in the past 3 months, and (f) 
non-pharmacological therapies for fatigue that took place in the past 3 months. The full details of the enrolment 
criteria have been described previously22.
The medical ethics committee of the VU University Medical Center approved the TREFAMS-ACE programme 
(METc 2010/289; NL33451.029.10). Additionally, local feasibility statements were obtained from each participat-
ing medical centre. All study procedures performed were in accordance with the 1964 Helsinki Declaration and 
its later amendments or comparable ethical standards. Written informed consent was obtained from all individual 
participants included in the TREFAMS-ACE trials.
Fatigue scales. In the TREFAMS-ACE studies, four self-reported fatigue questionnaires were used.
The Checklist of Individual Strengths (CIS20r) is a multidimensional questionnaire that consists of 20 items, 
divided into four fatigue dimensions and related behavioural aspects, including: (a) the subjective experience 
of fatigue (8 items), (b) reduction in motivation (4 items), (c) reduction of physical activity (3 items), and (d) 
reduction in concentration (5 items)23,24. The CIS20r focuses on fatigue in the past 2 weeks and for each item the 
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person has to indicate on a 7-point scale to what extent the particular statement applies to her or him (yes, that is 
true – no, that is not true). However, information on the development phase of the CIS20r and the origin of the 
initial 24 items is missing23,25.
The Modified Fatigue Impact Scale (MFIS) is part of the Multiple Sclerosis Quality-of-Life Inventory (MSQLI), 
and assesses the perceived impact of fatigue on physical, cognitive, and psychosocial functioning9,26. From the 
questionnaire instructions it follows that “fatigue is a feeling of physical tiredness and lack of energy that many 
people experience from time to time”. Participants rate how often fatigue has affected 21 functions during the past 
4 weeks using a 5-point scale (0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = almost always). Besides a total 
MFIS score, subscale scores for physical (9 items), cognitive (10 items) and psychosocial fatigue (2 items) can 
be calculated9,26. The original 40-item Fatigue Impact Scale (FIS) was developed based on interviews of patients 
with MS about how fatigue affects their daily activities and social life27. The MFIS was derived from the FIS by a 
consensus meeting of an expert panel of the US National Multiple Sclerosis Society9,26.
The Fatigue Severity Scale (FSS) is an unidimensional questionnaire of 9 statements evaluating the severity but 
also the impact of fatigue in patients with MS. Items are scored from 1 to 7 (1 = completely disagree to 7 = com-
pletely agree)28. During development of the FSS, theoretical considerations and factor analysis were used to select 
the 9 items. Items were selected based on their ability to identify common features of fatigue in patients with MS 
and Systemic Lupus Erythematosus as compared to healthy controls28. Eight items ask about physical aspects of 
fatigue and the interference of fatigue in activities and responsibilities, and one item is related to cognitive aspect 
of fatigue (i.e. motivation is lower when fatigued). FSS scores are the mean (1–7) or the sum of the item scores 
(9–63), with lower scores indicating less fatigue.
The SF36 vitality scale is one of the subscales of the SF36, and consists of four items (i.e. feel full of life; having 
a lot of energy; feel worn out; feel tired), with a five-point frequency rating scale ranging from “all of the time” to 
“none of the time. The SF36 is a generic Quality of Life questionnaire, using a 4-week time frame. SF36 vitality 
yields a score on a 0–100 scale, with higher scores indicating more vitality29.
The MFIS and FSS are two well-known questionnaires that are used worldwide in MS rehabilitation research. 
The SF36 vitality subscale is usually not assessed independently, but as part of the (total) SF36. The multidimen-
sional CIS20r is perhaps a quite new questionnaire in the field of MS. This valid and responsive questionnaire was 
the primary outcome in many RCTs on Cognitive Behavioural Therapy for fatigue in various diagnostic patient 
groups (e.g. Chronic Fatigue Syndrome, Diabetes, Cancer-related fatigue)25. The various time frames patients 
should have in mind when answering each set of fatigue questions differ, and were in this study not aligned to 
each other.
Other measures. The baseline study questionnaire also included questions regarding socio-demographic 
characteristics (e.g. age, gender, level of education, employment status, living situation) and disease characteris-
tics (e.g. date of diagnosis, date of first complaints, current type of MS). MS characteristics were also part of the 
enrolment examination by a rehabilitation physician.
Statistical analysis. Together, the CIS20r, MFIS, FSS and SF36 vitality consist of nine fatigue subscale scores 
and 54 item scores. For each of the participants their baseline scores were used. All analyses were conducted using 
IBM SPSS 22.0 (Statistical Package for the Social Science). To study the distribution of scores, the floor and the 
ceiling effects of the nine subscales were studied by calculating the percentage of patients with the lowest or the 
highest scores on each subscale. At baseline, we expected no floor effects but possible ceiling effects (reversed for 
the SF36 vitality).
Pearson correlation coefficients between subscale scores were calculated within and between the four fatigue 
questionnaires. Multicollinearity (defined as a bivariate correlation > 0.70) was examined to ensure that the scales 
were not closely related.
Cluster analysis. There are various methodological approaches to identifying clinically important subgroups 
and one method is to identify clusters of characteristics that differentiate people using Cluster analysis30,31. Cluster 
analysis was applied using SPSS’s two-step clustering algorithm31. To facilitate interpretation of the results of the 
cluster analyses, the nine subscale scores were transformed into z-scores (mean 0, SD 1). Scores were checked for 
normal distribution. The clustering algorithm results in a number of clusters, and assigns patients to clusters so 
that the means for all variables are as different from each other as possible for the different clusters30,31. Such a 
clustering approach is useful in MS-related fatigue where there is known heterogeneity in perceived fatigue that 
might characterize patients with common fatigue profiles. In contrast to factor analytic approaches to test the 
scale constructs, cluster analysis is a person-centred technique32. The optimal number of clusters was automati-
cally determined, using Schwarz’ Bayesian Information Criterion. As a measure of dissimilarity between groups 
the squared Euclidean distance between each pair of observations was used, where shorter distances indicated 
greater similarity. Ward’s hierarchical clustering method, which seeks to minimize the sum of squared errors 
between the groups regarding all variables, was used to verify the outcome of the two step clustering30,31. After 
evaluation of the data and the dendrogram plot, the groups were chosen based on the statistical significance of 
differences between the clusters. In order to validate the results obtained from the cluster analysis, an accurate 
discriminant function was estimated for classification of the MS patients in the fatigue profiles (clusters) formed. 
The classification accuracy of the estimated discriminant function was determined by the number of correctly 
classified individuals.
Factor analysis. In the next step, we tested if the 54 fatigue item scores behaved in accordance with a single, 
that is unidimensional, factor model, using factor analysis (principal axis factoring). The combined items were 
considered unidimensional if only one factor was extracted with an Eigenvalue equal to or greater than 1, with a 
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percentage of explained variance of at least 50%33. Once unidimensionality was rejected, we used factor analysis 
to gain insights into the underlying dimensional structure of the combined 54 items, based on principal axis fac-
toring with an oblimin rotation, permitting the underlying factors to be correlated.
Results
Patients. Table 1 shows the socio-demographic and disease-related characteristics of 264 participants with 
primary MS-related fatigue. The median duration of MS was 6.8 years, with a median Expanded Disability Status 
Scale (EDSS) disease severity score of 2.5 (range 0–6), a mean age of 48.1 years (range 19–68 yrs.) and 75% were 
women.
Distribution of fatigue scores. Mean scores on all fatigue subscales, as well as the percentage floor and 
ceiling effects are shown in Table 2. Overall, floor and ceiling effects were small (<5%). However, against expec-
tations, two of the three MFIS subscales and three of the four CIS20r subscales showed some floor effects in this 
study group of severely fatigued patients. Some participants reported maximum fatigue scores on the CIS20r 
subscales, the FSS, and MFIS psychosocial. Participants had mean fatigue scores of 5.3 on the FSS (SD 0.9), 92.0 
(SD 17.2) on the CIS20r total, 44.2 (SD 12.3) on the MFIS total and 41.9 (SD 14.2) on the SF36 vitality.
Correlation of fatigue subscales. Table 3 shows the correlation coefficients within and between fatigue 
scales. In general, most correlations were low, indicating that despite some overlap the subscales were measuring 
different constructs and illustrate the multidimensional character of MS-related fatigue. The low correlation of the 
FSS with nearly all other subscales provides evidence that the FSS is measuring a different aspect of fatigue. The 
subscale correlations within the CIS20r are lower than the correlations within the MFIS. This table also shows that 
the MFIS cognitive subscale and the CIS20r concentration subscale are highly correlated (r = 0.799), seemingly 
measuring the same construct.
Demographic characteristic Median/N Range/%
Age (yrs) 48.1 19.6–68.1
Gender
Male 66 25
Female 198 75
Level of Education
Low 17 6.4
Intermediate 122 46.2
High 125 47.3
Disability pension
No 113 42.8
Yes, partial 50 18.9
Yes, full 101 38.3
Employmenta
Full-time 28 10.7
Part-time 99 37.9
Not 119 45.6
(Early) retirement 10 3.8
Student 5 1.9
Living arrangement
Living with partner 204 77.3
Living alone/with children/other 60 22.7
Disease characteristics
Type of MS
Relapsing-Remitting 190 72
Primary Progressive 24 9.1
Secondary Progressive 32 12.1
Unknown 18 6.9
Duration of MS (yrs) 6.8 0.14–30.7
EDSS 2.5 0.0–6.0
Member of a patient organisationa
Yes 119 45.4
No 143 54.6
Table 1. Demographic and disease-related characteristics of the 264 patients with primary MS-related fatigue. 
aDue to missing values the total number is not equal to 264. Abbreviations: EDSS – Expanded Disability Status 
Scale, MS – Multiple Sclerosis, yrs - years.
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Fatigue profiles. The cluster analysis was based on complete data from 262 patients and initially resulted in 
a two-profile solution. The CIS20r concentration was excluded from the cluster analysis due to multicollinearity 
of the subscales CIS20r concentration and MFIS cognitive. The first fatigue profile included 88 patients with 
relatively low average scores on all subscales, whereas patients with the other profile had relatively high scores 
on all subscales (Table 4a). At the expense of losing some accuracy in patient classification, we also investigate a 
three-cluster solution. From the large cluster (174 patients) another profile was extracted that included fatigued 
patients with average scores (z-scores close to 0) who were therefore less troubled by cognitive fatigue, vitality, and 
physical activities compared to members of the third profile who showed high scores on all subscales (Table 4b). 
This three-profile solution correctly classified 86.3% of the patients, whereas the two profiles correctly classified 
96.6% of the patients (Table 4).
These fatigue profiles could not be intuitively linked to the clinically expected dimensions of MS-related 
fatigue, which includes physical, cognitive or mental fatigue, or the psychosocial or distress dimension (with 
the subscales reduced motivation and reduced activities). The distinction between these profiles was due to the 
severity of the fatigue, evidenced by the high vs. low z-scores on all subscales.
Unidimensionality. Factor analysis of all 54 items showed that there was no unidimensionality among the 
54 items. Eight factors with Eigenvalues equal to or greater than 1.0 were extracted, which together explained 
57.1% of the total variance (Table 5). The first factor with a loading of 11/54 items explained only 31% of the total 
variance. The results of the item-to-factor loadings are presented in Table 6. A minimum item-factor loading of 
0.500 was found in 39/54 items. In nine items, all with low factor loadings, the difference in loadings on several 
factors was small (<0.200), meaning that these items could not be uniquely assigned to one of the eight factors. 
Table 6 shows that the items of subscales of the CIS20r, MFIS, and the FSS almost all load on their own factor 
(e.g. CIS20r fatigue items load on factor 1, the highly correlated CIS20r concentration items and MFIS cognitive 
items load on factor 2, MFIS physical items load on factor 3, CIS20r motivation load on factor 4, FSS items load 
on factor 5 and 7, CIS20r physical activities load on factor 6, and factor 8 contains one CIS20r fatigue item that 
also loads on factor (1). The eight factors almost confirm the original factor structure of the subscales of the 4 
included fatigue questionnaires.
Measure Items
Theoretical 
Range Mean (sd)
Floor 
Effect %
Ceiling 
Effect %
CIS20r total 20 20–140 92.0 (17.2) 0 0
CIS20r fatigue 8 8–56 43.3 (7.7) 0 1.9
CIS20r concentration 5 5–35 20.9 (7.6) 2.3 2.3
CIS20r motivation 4 4–28 15.1 (5.4) 1.5 0.8
CIS20r phys. activities 3 3–21 12.8 (4.8) 2.3 4.9
MFIS total 21 0–84 44.2 (12.3) 0 0
MFIS physical 9 0–36 21.0 (5.4) 0 0
MFIS cognitive 10 0–40 19.2 (7.8) 0.4 0
MFIS psychosocial 2 0–8 4.0 (1.7) 4.5 1.1
FSS 9 1–7 5.3 (0.9) 0 0.4
SF36 vitality 4 0–100 41.9 (14.2) 0 0
Table 2. Scores on the fatigue subscales. Abbreviations: CIS20r - Checklist of Individual Strength, FSS - Fatigue 
Severity Scale, MFIS - Modified Fatigue Impact Scale, sd – standard deviation, SF36 vitality – Short Form 36 
vitality.
CIS20r 
concentration
CIS20r 
motivation
CIS20r physical 
activities
MFIS 
physical
MFIS 
cognitive
MFIS  
psycho-social FSS
SF36 
vitality
CIS20r fatigue 0.219 0.293 0.340 0.499 0.198 0.431 0.403 −0.640
CIS20r concentration 0.227 0.247 0.210 0.799 0.282 0.243 −0.290
CIS20r motivation 0.320 0.244 0.250 0.344 0.201 −0.355
CIS20r phys. activities 0.387 0.292 0.340 0.289 −0.357
MFIS physical 0.423 0.657 0.383 −0.393
MFIS cognitive 0.436 0.271 −0.357
MFIS psychosocial 0.436 −0.446
FSS −0.355
Table 3. Pearson correlation coefficients of fatigue subscales in 264 patients with MS. Abbreviations: CIS20r -  
Checklist of Individual Strength, FSS - Fatigue Severity Scale, MFIS - Modified Fatigue Impact Scale, sd – 
standard deviation, SF36 vitality – Short Form 36 vitality. The direction of the SF36 vitality is opposite to the 
direction of the other scales, resulting in negative coefficients. All correlations were significant at the 0.01 level 
(2-tailed).
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Discussion
This study aimed to discover subgroups of MS patients with comparable fatigue complaints, and resulted in the 
identification of three homogeneous profiles of primary MS-related fatigue. However, the identified fatigue pro-
files did not show that existing fatigue domains were decisive in the formation of the clusters. Fatigue profiles 
mainly distinguished patients based on the severity of their score on all domains. The multiple dimensions of 
fatigue had no influence on cluster formation. Therefore, in patients with a treatment indication due to severe 
primary MS-related fatigue, the fatigue profile solutions are not helpful in more appropriate targeting of the opti-
mal fatigue intervention. Also in other diagnostic groups (i.e. Parkinson’s Disease, Colorectal Cancer), patient 
profiling did not result in clear differentiation based on the most affected fatigue domains34,35. An explanation 
for the absence of distinct profiles for type of fatigue might be related to the inability of patients to make further 
distinctions when fatigue becomes very severe. This fits with the theoretical model of low energy in chronically 
ill patients described by Lerdal36. The Unidimensional Fatigue Impact Scale (U-FIS) developed in MS patients 
showed from the item hierarchy found that the physical aspects of fatigue represent mild levels of the functional 
impact of fatigue, cognitive aspects capture moderate levels of fatigue impact and emotional aspects represent the 
most severe levels of fatigue impact37.
A. Two fatigue profile solution
Z-scores
Profile 1 
n = 88
Profile 2 + 3 
n = 174
CIS20r fatigue −0.73 0.37
CIS20r motivation −0.37 0.19
CIS20r phys. activities −0.48 0.25
MFIS physical −0.96 0.48
MFIS cognitive −0.56 0.28
MFIS psychosocial −1.00 0.50
FSS −0.78 0.40
SF36 vitality 0.71 −0.37
B. Three fatigue profile solution
Z-scores Profile 1 n = 88
Profile 2 
n = 96
Profile 3 
n = 78
CIS20r fatigue −0.73 0.22 0.57
CIS20r motivation −0.37 −0.39 0.90
CIS20r phys. activities −0.48 −0.04 0.59
MFIS physical −0.96 0.31 0.69
MFIS cognitive −0.56 0.05 0.57
MFIS psychosocial −1.00 0.36 0.68
FSS −0.78 0.47 0.32
SF36 vitality 0.71 −0.10 −0.70
Table 4. Cluster analyses resulted in two (A) or three fatigue profiles (B). (A) 96.6% of the patients were 
correctly classified. (B) 86.3% of the patients were correctly classified.
Total Variance Explained
Factor
Initial Eigenvalues Extraction Sums of Squared Loadings
Rotation Sums of 
Squared Loadingsa
Total
% of 
Variance Cumulative % Total
% of 
Variance Cumulative % Total
1 17.144 31.749 31.749 16.743 31.006 31.006 8.804
2 5.946 11.012 42.760 5.561 10.297 41.304 11.960
3 2.872 5.319 48.079 2.440 4.519 45.822 7.510
4 2.399 4.443 52.523 1.955 3.620 49.442 6.304
5 1.888 3.497 56.019 1.438 2.664 52.105 5.578
6 1.587 2.938 58.958 1.185 2.195 54.300 7.554
7 1.294 2.396 61.354 0.801 1.484 55.784 2.932
8 1.171 2.169 63.523 0.727 1.347 57.131 3.525
9 0.962 1.782 65.305
10b 0.937 1.736 67.041
Table 5. Results of the Factor Analysis of 54 Fatigue Questions from four Fatigue Questionnaires. aWhen 
factors are correlated, sums of squared loadings cannot be added to obtain a total variance. bTable has been 
shortened after 10 of 54 factors. Extraction Method: Principal Axis Factoring. Rotation Method: Oblimin with 
Kaiser Normalization.
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Fatigue Item
Factor
1 2 3 4 5 6 7 8
CIS20r_1c_fatigue 0.765
CIS20r_2_motivation 0.180 0.593 0.186
CIS20r_3c_conc 0.132 0.802 −0.137
CIS20r_4c_fatigue 0.642 −0.102 0.321
CIS20r_5_motivation 0.740
CIS20r_6_fatigue 0.578 0.235
CIS20r_7_act 0.839 −0.109
CIS20r_8_conc 0.778 −0.180 0.119
CIS20r_9c_fatigue 0.227 0.549
CIS20r_10c_act 0.858
CIS20r_11_conc 0.841 −0.236
CIS20r_12_fatigue 0.678 0.109
CIS20r_13c_conc 0.730 −0.218 0.100
CIS20r_14c_fatigue* 0.329 0.119 0.125 0.121 0.296
CIS20r_15_motivation 0.810 0.125
CIS20r_16c_fatigue 0.643 0.108 0.138
CIS20r_17c_act 0.139 0.619
CIS20r_18c_motivation 0.575 0.150
CIS20r_19c_conc 0.742 −0.187 0.178
CIS20r_20_fatigue 0.454 0.112 0.186 0.170 0.144
SF36_23c −0.508 −0.188
SF36_27c* −0.417 −0.306 −0.126 −0.107
SF36_29 −0.541 −0.155 −0.108 −0.179
SF36_31 −0.746 −0.112
FSS_1 0.148 0.147 0.419
FSS_2 −0.111 0.358 0.117
FSS_3* 0.468 0.203 0.326 −0.102
FSS_4* 0.432 0.438
FSS_5 0.492 0.220 0.248
FSS_6 0.169 0.150 0.644 −0.116
FSS_7 0.103 0.493 0.256 0.275
FSS_8* 0.344 0.448 −0.158
FSS_9 0.160 0.617 0.144
MFIS_1_cognitive 0.131 0.573 0.228 0.136 −0.139
MFIS_2_cognitive 0.134 0.758 0.151 −0.120
MFIS_3_cognitive 0.739 0.116
MFIS_4_fys* 0.361 0.338 0.159 0.106
MFIS_5_cognitive 0.695 0.170
MFIS_6_fys 0.118 0.567 −0.104 0.129 0.218
MFIS_7_fys 0.542 0.201 0.128 −0.155
MFIS_8_psychosoc* 0.134 0.383 0.218 0.318 −0.245
MFIS_9_psychosoc 0.505 0.105 0.147 0.160
MFIS_10_fys 0.118 0.580 0.135 0.306
MFIS_11_cognitive −0.127 0.566 0.177 0.136 −0.108
MFIS_12_cognitive 0.649 0.169 0.124 −0.150
MFIS_13_fys* 0.398 0.180 0.387
MFIS_14_fys 0.247 0.457 0.220
MFIS_15_cognitive 0.761 0.166
MFIS_16_cognitive 0.769 0.150
MFIS_17_fys 0.117 0.595 0.144 0.183
MFIS_18_cognitive 0.767 0.153
MFIS_19_cognitive 0.869 −0.112
MFIS_20_fys 0.667 0.158 0.107
MFIS_21_fys* 0.300 0.465 −0.108 0.121
Table 6. Pattern Matrix of Factor Analysis of 54 fatigue items from the CIS20r, FSS, SF36 vitality and MFIS. 
Extraction Method: Principal Axis Factoring, Rotation Method: Oblimin with Kaiser Normalization, Rotation 
converged in 25 iterations. Small item-to-factor loadings < −0.100–0.100 > are not presented. For each item 
the highest factor loading in bold. Fatigue items marked with an asterix do not discriminate enough and are 
actually redundant. In Italic: items with loading difference  < 0.200.
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Although the results of the cluster analysis suggested that fatigue may be an unidimensional construct, the fac-
tor analysis clearly showed that an unidimensional fatigue scale could not be confirmed. Factor analysis showed 
evidence for eight fatigue factors, comparable to most of the subscales of the questionnaires used in this analysis. 
This endorses the multidimensional nature of fatigue.
The dimensionality of the CIS20r and MFIS have already been repeatedly investigated by others, mostly con-
firming the multidimensionality of both scales25,38–40. The MFIS is commonly used to generate an overall score 
of fatigue. However, its 21 items do not fit the unidimensional Rasch model mainly because of multidimen-
sionality41,42. Valid physical and cognitive subscales of the MFIS were derived after deletion of some items41. In 
their paper, Lundgren-Nilsson et al. present a 15- and a 6-item Rasch transformed interval fatigue scale fulfilling 
unidimensionality and a transformation table to adjust scores derived from the original MFIS42. For the FSS, item 
reductions have been proposed in response to non-fitting items43,44.
Recently, some unidimensional fatigue scales were developed in which fatigue is actually considered a continuum45. 
The PROMIS fatigue item bank (PROMIS stands for Patient Reported Outcomes Measurement Information System) 
consists of 95 items (including 4 items of the SF36 vitality) and measures the experience of fatigue and its impact 
on daily functioning46. With regard to cancer-related fatigue, the EORTC fatigue item bank (44 items) specifically 
aims at measuring general and physical fatigue47. Another cancer-related fatigue bank of 72 items, covering various 
aspects of fatigue, explained 57.5% of the fatigue variance with one factor48. Fatigue item banks are useful in computer 
adaptive testing. However, it should be noted that due to strict requirements of the Rasch model or Item Response 
Theory models, measurement rigor and assumptions, the fatigue construct of the remaining items and short forms (e.g. 
PROMIS-Fatigue(MS)) is increasingly fading40,49–51. In contrast to these unidimensional fatigue scales and item banks, 
construct validation of fatigue in rheumatoid arthritis resulted in a multidimensional computerized adaptive test52.
De Raaf et al.53 considered three options for the nature of fatigue: the unidimensional concept, the multidimen-
sional concept, and the multiple symptoms concept. In the multiple symptoms concept of fatigue these authors pro-
posed that fatigue might not be one, albeit multidimensional, symptom or concept, but an expression of separate 
symptoms that are collectively called fatigue. Each symptom represents an unidimensional scale and scores of the 
different symptoms cannot be summed. Supportive of the multiple symptoms concept of fatigue, de Raaf et al.53 
argued that (1) symptoms respond differently to their intensity in cross-sectional studies comparing various 
groups of patients, (2) the course of the intensity of symptoms is different in longitudinal follow-up studies, (3) 
symptoms correlate differently with other variables, and (4) symptoms behave differently in their response to 
interventions aimed at relieving fatigue. Furthermore, the pathogenesis of symptoms may differ, and symptoms 
show low mutual correlation. The low mutual correlations of the CIS20r subscales and the MFIS subscales found 
in our study (Table 3) might be indications for the multiple symptoms concept of fatigue.
The following study limitations should be considered. The study population purposely consisted of severely 
fatigued patients with MS. The CIS20r fatigue subscale was used to screen trial participants. We suspect that using 
for instance the FSS or the MFIS as screening instrument, would have led to small changes in the composition of 
the study population, with some participants not being included, and others being included. Scores on all four 
fatigue questionnaires were not available for non-fatigued patients, and those patients that were excluded during 
the screening process. However, the aim of our study was not to discriminate non-fatigued patients from fatigued 
patients, but primarily to profiling severely fatigued patients in order to specify their treatment and improve 
treatment efficiency. We assume that the inclusion of non-fatigue MS patients may have even strengthened the 
profiles based on the severity scores. Furthermore, we used cluster analysis and factor analysis on the same data-
set, which might seem unusual at first glance32. Cluster analysis of fatigue subscale scores aimed to identify par-
ticular clusters of individuals showing the same fatigue pattern, whereas factor analysis of the fatigue items was 
applied to study the dimensionality of fatigue and the type of fatigue items that grouped together. The FSS and the 
SF36 vitality were considered unidimensional. The CIS20r and the MFIS were constructed as multidimensional 
scales, although the use of total CIS20r and MFIS scores is still commonplace. Based on the outcome of the cluster 
analysis and in view of the constructs of the four fatigue questionnaires, we nevertheless decided to investigate 
the factor structure of the fatigue items under the assumption that a unidimensional scale could be distinguished.
Almost 90% of the participants (n = 234) preferred to complete the internet questionnaire. Due to this large 
imbalance with those participants who wanted to complete the paper version, we did not perform sensitivity 
analyses to investigate whether paper and internet assessments led to different clusters or factors.
Generalizability of the findings should be related to our aim and study population.
Conclusions
Fatigue related to Multiple Sclerosis (MS) is considered a multidimensional symptom, manifesting in several 
dimensions such as physical, cognitive, and psychosocial fatigue. The present cross-sectional study applied cluster 
analysis to the nine fatigue subscales with the objective of identifying distinct fatigue profiles that might require 
different rehabilitation treatment approaches in patients with primary MS-related fatigue. The fatigue profiles 
discovered did not differentiate between clinically expected dimensions of fatigue. One unidimensional fatigue 
construct within the 54 fatigue questions could not be confirmed, and the four fatigue instruments CIS20r, MFIS, 
FSS and SF36 vitality appear to measure different fatigue constructs.
The results of this study imply that for diagnosis and initiation of fatigue treatment, one simple fatigue (sub-)
scale, such as the CIS20r fatigue, is sufficient. No currently available study has shown that dimension-specific 
treatment of fatigue leads to better outcomes. In terms of clinical practice this means that there is as yet no reason 
to measure multidimensional aspects of fatigue in primary fatigued patients with MS.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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